Literature DB >> 1654899

Attenuation of daunorubicin-augmented microsomal lipid peroxidation and oxygen consumption by calcium channel antagonists.

F N Engineer1, R Sridhar.   

Abstract

Daunorubicin (20 microM) stimulated NADPH-dependent microsomal lipid peroxidation about 2-fold over control values and enhanced the rate of oxygen utilization by microsomes. The calcium channel blockers tested inhibited daunorubicin-augmented lipid peroxidation and O2 consumption to varying degrees. Inhibition of daunorubicin-stimulated lipid peroxidation was found to be dose dependent; the IC50 (drug concentration producing 50% inhibition of lipid peroxidation) values for verapamil, nifedipine and diltiazem were approximately 150 microM, 200 microM, and 600 microM respectively. Our in vitro studies suggest that calcium channel antagonists may modulate the free radical-mediated, cardiotoxic effects of daunorubicin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1654899     DOI: 10.1016/0006-291x(91)91933-4

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Nicotine decreases the cytotoxicity of doxorubicin towards MCF-7 and KB-3.1 human cancer cells in culture.

Authors:  Yanfei Zhou; Xinbin Gu; Ebrahim Ashayeri; Renshu Zhang; Rajagopalan Sridhar
Journal:  J Natl Med Assoc       Date:  2007-04       Impact factor: 1.798

2.  The effect of ghee (clarified butter) on serum lipid levels and microsomal lipid peroxidation.

Authors:  Hari Sharma; Xiaoying Zhang; Chandradhar Dwivedi
Journal:  Ayu       Date:  2010-04

3.  In vitro study of the binding of doxorubicin to heart.

Authors:  L Alvarez-Cedrón; F G López; J M Lanao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.569

4.  Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply.

Authors:  C H Thompson; V M Macaulay; K J O'Byrne; G J Kemp; S M Wilner; D C Talbot; A L Harris; G K Radda
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.